BeiGene
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 2018-06-28
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.beigene.com
- Introduction
The company's mission is to become a global leader in the discovery, development and commercialization of innovative molecular-targeted immuno-oncology drugs to treat cancer. The company focuses on R&D, production and commercialization of innovative drugs. The main products are anti-tumor drugs, etc.
Clinical Trials
77
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials
News
Jazz Pharmaceuticals Advances Pipeline with Zanidatamab BLA Acceptance and Strong Financial Performance
• Jazz Pharmaceuticals' Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, has been accepted by the FDA with Priority Review for biliary tract cancer. • The company reported strong financial results in 2023, with over $3.8 billion in total revenue and $1.6 billion in cash reserves, supporting continued investment in R&D. • Jazz Pharmaceuticals is actively expanding its oncology and neuroscience portfolio through strategic collaborations and internal development, focusing on unmet medical needs. • Key products like Xyrem, Xywav, Zepzelca, Rylaze, and Epidiolex continue to drive revenue, while ongoing trials aim to broaden indications and improve patient outcomes.